comparemela.com

Latest Breaking News On - Biosciences stock down - Page 5 : comparemela.com

Truist Financial Reiterates Buy Rating for Caribou Biosciences (NASDAQ:CRBU)

Truist Financial restated their buy rating on shares of Caribou Biosciences (NASDAQ:CRBU – Free Report) in a report published on Thursday, Benzinga reports. Truist Financial currently has a $19.00 price target on the stock. Separately, HC Wainwright reaffirmed a buy rating and issued a $24.00 price target on shares of Caribou Biosciences in a research […]

United-states
Deerfield-management-companylp-series
Alkeon-capital-management
Caribou-biosciences-company-profile
Caribou-biosciences-inc
Vanguard-group-inc
Truist-financial
Caribou-biosciences
Free-report
Biosciences-stock-down
Get-free-report

GW&K Investment Management LLC Sells 18,829 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

GW&K Investment Management LLC lessened its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 3.4% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 535,962 shares of the company’s stock after selling 18,829 shares during the period. […]

United-states
Los-angeles
California
Eric-benevich
Neurocrine-biosciences
Gwk-investment-management
Goldman-sachs-group
Needham-company
Los-angeles-capital-management
Jacobs-levy-equity-management-inc
Norges-bank
Exchange-commission

Akoya Biosciences, Inc. Forecasted to Earn Q2 2024 Earnings of ($0.28) Per Share (NASDAQ:AKYA)

Akoya Biosciences, Inc. (NASDAQ:AKYA – Free Report) – Capital One Financial lowered their Q2 2024 EPS estimates for shares of Akoya Biosciences in a research note issued on Monday, May 13th. Capital One Financial analyst T. Chiang now expects that the company will earn ($0.28) per share for the quarter, down from their prior estimate […]

United-states
America
Akoya-biosciences
Akoya-bioscience
Asia-pacific
Brian-mckelligon
Jpmorgan-chase-co
Nasdaq
Akoya-biosciences-inc
Asset-management-inc
Silvercrest-asset-management-group
Tower-research-capital

Akoya Biosciences, Inc. (NASDAQ:AKYA) to Post Q2 2024 Earnings of ($0.28) Per Share, Capital One Financial Forecasts

Akoya Biosciences, Inc. (NASDAQ:AKYA – Free Report) – Stock analysts at Capital One Financial dropped their Q2 2024 earnings per share estimates for Akoya Biosciences in a research note issued on Monday, May 13th. Capital One Financial analyst T. Chiang now expects that the company will post earnings of ($0.28) per share for the quarter, […]

United-states
America
Brian-mckelligon
Akoya-bioscience
Asia-pacific
Akoya-biosciences
Asset-management-inc
Canaccord-genuity-group
Nisa-investment-advisors
York-mellon-corp
Akoya-biosciences-inc
Tower-research-capital

14,020 Shares in Coherus BioSciences, Inc. (NASDAQ:CHRS) Purchased by Baader Bank Aktiengesellschaft

14,020 Shares in Coherus BioSciences, Inc. (NASDAQ:CHRS) Purchased by Baader Bank Aktiengesellschaft
wkrb13.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from wkrb13.com Daily Mail and Mail on Sunday newspapers.

Switzerland
United-states
Swiss
Robertw-baird
Coherus-biosciences
Hsbc-holdings
Vanguard-group-inc
Nasdaq
Baader-bank-aktiengesellschaft
Swiss-national-bank
Brandywine-global-investment-management
Campbell-co-investment-adviser

vimarsana © 2020. All Rights Reserved.